Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023)
Roivant Sciences (ROIV) posted Net Equity Issued and Repurchased of $199.8 million for Q4 2023, up 110.93% on a QoQ basis from $94.7 million in Q4 2022, and up 110.93% year-over-year from $94.7 million in Q4 2022.
Roivant Sciences (ROIV) Net Equity Issued and Repurchased (2022 - 2023) Analysis & Trends
Roivant Sciences' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $199.8 million for Q4 2023.
- Quarterly Net Equity Issued and Repurchased rose 110.93% year-over-year to $199.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2024 was $294.6 million (changed N/A YoY) and the FY2024 annual result came in at $199.8 million, down 35.95% from the prior year.
- Net Equity Issued and Repurchased was $199.8 million for Q4 2023 at Roivant Sciences, up from $94.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $199.8 million in Q4 2023 and bottomed at $94.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 199.82 Mn |
| Dec 31, 2023 | 199.82 Mn |
| Dec 31, 2022 | 94.74 Mn |
| Dec 31, 2022 | 94.74 Mn |